Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The incidence of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) is rising with the increasing use of next-generation imaging. Local radiotherapy (RT) was shown to improve survival in patients with mHSPC; however, new data require a re-assessment of the indication and value of local RT in mHSPC.
Methods: In this prospectively registered systematic review and -analysis (CRD42025648251), we searched MEDLINE, Scopus, CENTRAL, and Google Scholar in March 2025 for phase 3 RCTs evaluating the addition of RT to systemic therapy to improve OS in mHSPC patients. Hazard ratios (HRs) were pooled using random-effects -analysis. Risk of Bias was assessed with Cochrane's RoB 2 tool.
Results: Out of the 10,615 individual records, we identified three RCTs: HORRAD (n = 432), STAMPEDE (n = 2,061), and PEACE-1 (n = 1,173). The systemic treatment included androgen deprivation therapy (ADT) in HORRAD, ADT ± Docetaxel in STAMPEDE, and ADT ± Docetaxel ± Abiraterone in PEACE-1 trial. Local RT was not associated with significantly improved OS in all patients (HR = 0.92; 95 % confidence interval [CI] 0.85-1.00; p = 0.06), or in those with low metastatic burden (HR = 0.74; 95 %CI 0.51-1.06; p = 0.1); however, exploratory analyses showed a significant improvement in androgen deprivation resistance-free survival (HR = 0.76; 95 %CI 0.70-0.82; p < 0.001). Local RT was associated with significant reduction in local prostate cancer related events in the HORRAD (18 % vs. 30 %) and PEACE-1 (12 % vs. 22 %) trials, but not in the STAMPEDE trial (49 % vs. 51 %).
Conclusion: Local RT does not improve OS in unselected patients treated with modern systemic therapies for mHSPC. However, it delays ADT resistance and reduces local adverse events, with relatively tolerable toxicity. Future studies should refine selection criteria, ideally using PSMA-PET imaging, dynamic response markers, and/or genomic profiling, to identify mHSPC patients most likely to benefit from local RT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272608 | PMC |
| http://dx.doi.org/10.1016/j.ctro.2025.101009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
Cancer
September 2025
Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Introduction: Treatment intensification with androgen receptor signaling inhibitors and/or chemotherapy is guideline recommended for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). However, most patients only receive androgen deprivation therapy monotherapy. The aim was to identify physician-, patient-, and tumor-related factors associated with the receipt of treatment intensification.
View Article and Find Full Text PDFProstate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.
Prostate
September 2025
Instituto Valenciano de Oncología, Valencia, Spain.
Background: PSA response to apalutamide combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) has been linked to prognosis. Post hoc analyses from clinical trials suggest that PSA levels at 6 months are critical for predicting radiographic progression-free survival (rPFS) and overall survival (OS). Real-world evidence (RWE) is needed to confirm these findings.
View Article and Find Full Text PDFNeuropilin-1 expression in primary and metastatic prostate cancer: Expression patterns and clinicopathological correlations.
Mol Clin Oncol
October 2025
University Centre of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Despite significant advancements in prostate cancer (PCa) diagnostics, it remains a challenge for accurate diagnosis and effective treatment. The aging global population and the established correlation between PCa incidence and advancing age suggest an anticipated rise in cases. Traditional clinicopathological parameters, such as prostate-specific antigen (PSA) levels, Gleason Grade Group, and pT stage, highlight the need for novel biomarkers to improve prognostic accuracy and risk assessment.
View Article and Find Full Text PDFTreatment Landscape for Older Men With Metastatic Hormone-Sensitive Prostate Cancer in the United States.
Cancer Med
September 2025
University of North Texas Health Science Center, Fort Worth, Texas, USA.
Objective: This study evaluated treatment patterns and factors associated with androgen deprivation therapy (ADT) intensification with androgen receptor pathway inhibitors (ARPI) and/or docetaxel among older men with mHSPC in the United States.
Methods: The study utilized a retrospective cohort of 6850 older men (age ≥ 67 years) diagnosed with mHSPC between July 2016 and December 2019 from the Surveillance, Epidemiology, and End Results Medicare-linked database. Men must maintain continuous enrollment in Medicare fee-for-service Parts A/B/D for ≥ 12 months before mHSPC diagnosis and ≥ 6 months after diagnosis.
Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: A modified Delphi study.
Investig Clin Urol
September 2025
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Purpose: Consensus is lacking among South Korean urologists on the appropriate treatment of metastatic hormone-sensitive prostate cancer (mHSPC). A modified, Delphi-based consensus on managing mHSPC patients was developed to support clinical decision-making.
Materials And Methods: Thirty-six questions on mHSPC treatment were developed by an expert committee (five urologists).